Sermorelin vs Ipamorelin vs Tesamorelin: Three Routes to GH

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

Research peptides that raise growth hormone fall into two families with different receptors. GHRH analogues (sermorelin, tesamorelin, CJC-1295) act on the GHRH receptor. Growth hormone secretagogues (ipamorelin, GHRP-2, GHRP-6, and the small molecule MK-677) act on the ghrelin receptor. Comparisons only make sense once that split is clear, because the two families differ in signalling, in how they shape GH pulses, and in how much evidence exists.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Summary card of the comparison table from the sermorelin vs ipamorelin vs tesamorelin research article — Summary of the table in this article; the cited sources are listed under References.

Key points

GHRH receptor family: sermorelin (1-29), tesamorelin (1-44, capped), CJC-1295 (1-29, substituted; DAC version albumin-bound).
Ghrelin receptor family: ipamorelin (pentapeptide), MK-677 (oral small molecule).
Tesamorelin has the strongest clinical dataset; ipamorelin has the cleanest selectivity profile.
No head-to-head trial compares them, so cross-study numbers cannot be ranked.
Blends pair one from each family to engage both routes.

The two families side by side

	GHRH receptor agonists	Ghrelin receptor agonists
Members here	Sermorelin, tesamorelin, CJC-1295	Ipamorelin, GHRP-2/6, MK-677
Receptor	GHRH-R, class B GPCR, mainly cAMP signalling	GHSR-1a, with constitutive activity modulated by ghrelin and LEAP2
Natural ligand	GHRH (hypothalamic)	Ghrelin (gut)
Typical size	29–44 residues	5–6 residues, or a non-peptide
Effect on GH pattern	Raises pulse amplitude and, for the DAC form, trough levels	Produces discrete GH episodes; MK-677 enhanced existing pulses

The receptor difference is not cosmetic. GHRH-R signalling is well described as a cAMP-driven pathway in somatotrophs (Halmos et al., 2025), while GHSR is unusual in having basal activity that two opposing endogenous ligands tune up or down (Cornejo et al., 2021). That is why antagonist experiments can separate the families cleanly: in the original ipamorelin work, GHRH antagonists did not block ipamorelin’s effect (Raun et al., 1998).

The individual compounds

Compound	Structure	Human evidence	Duration
Sermorelin	GHRH(1-29)-NH₂, unmodified	Paediatric GH deficiency trials; three daily administrations in one 6-month study	Short
Tesamorelin	GHRH(1-44) with trans-3-hexenoyl cap	Phase 3: visceral fat −15.2% vs +5.0% placebo at 26 weeks; IGF-I +81%	Once daily in trials
CJC-1295 with DAC	GHRH(1-29), four substitutions + albumin binder	GH 2–10× for ≥6 days; IGF-I 1.5–3× for 9–11 days; t_1/2 5.8–8.1 days	Days
CJC-1295 no DAC	Same core, no albumin binder	Limited published human PK	Short
Ipamorelin	Aib-His-D-2-Nal-D-Phe-Lys-NH₂	Phase 1 PK/PD: t_1/2 ~2 h; single GH episode peaking ~0.67 h	Hours
MK-677	Non-peptide, 624.8 g/mol	25 mg/day for 2 weeks raised mean 24-h GH 97%; IGF-I into the young-adult range	Oral, once daily

Profiles: tesamorelin, ipamorelin, CJC-1295. Sermorelin is available as sermorelin acetate.

Why blends pair one from each family

Because the receptors are distinct, a GHRH analogue and a secretagogue can be studied together to see whether combined stimulation differs from either alone. The common pairings are CJC-1295 (no DAC) with ipamorelin, and sermorelin with ipamorelin. We are not aware of peer-reviewed trials of these specific blends; the rationale rests on the separate receptor literature rather than on combination data. See CJC-1295 + ipamorelin and GH peptide blends.

MK-677: the non-peptide in the group

MK-677 (ibutamoren) is included here because it appears in the same comparisons, but it is a small molecule, not a peptide. In 32 healthy adults aged 64–81, 25 mg daily for two weeks raised mean 24-hour GH by 97% and brought IGF-I into the young-adult range. The increase came from enhancement of existing pulsatile secretion: pulse height and interpulse nadir rose without a change in pulse number (Chapman et al., 1996). A later two-year trial in 65 healthy older adults reported increased fat-free mass versus placebo, with no significant difference in total fat mass (Nass et al., 2008). Being orally active and non-peptide, it needs none of the handling precautions the peptides do.

Choosing for an experiment

Research aim	Suitable tool
Isolate GHRH-receptor signalling	Sermorelin or tesamorelin
Model sustained GHRH-receptor stimulation	CJC-1295 with DAC
Isolate ghrelin-receptor signalling without ACTH/cortisol confounding	Ipamorelin
Compare peptide vs non-peptide secretagogue	Ipamorelin and MK-677
Examine combined pathway stimulation	A GHRH analogue plus a secretagogue

Whatever the design, measure GH frequently enough to catch short episodes, and remember IGF-I integrates exposure over days rather than reflecting a single GH peak.

Handling

All the peptides: lyophilized powder at −20 °C; solutions at 2–8 °C, dark; avoid repeated freeze–thaw.
Sermorelin and tesamorelin contain Met27 and are oxidation-sensitive; CJC-1295 replaces it with leucine.
Concentrations: peptide reconstitution calculator; method in how to reconstitute peptides.

Open questions

Would a head-to-head trial confirm the differences suggested by separate studies?
Does combined GHRH-R and GHSR stimulation give additive, synergistic or redundant GH responses?
How does prolonged stimulation of either receptor affect its responsiveness over weeks?

Frequently asked questions

What is the difference between sermorelin, ipamorelin and tesamorelin?

Sermorelin and tesamorelin are GHRH analogues acting on the GHRH receptor; ipamorelin is a pentapeptide acting on the ghrelin receptor (GHSR). Sermorelin is the unmodified GHRH(1-29) fragment, tesamorelin is full-length GHRH(1-44) with a protective N-terminal group.

Which of them has the most clinical data?

Tesamorelin, which has phase 3 trials and a licensed indication. Sermorelin’s trials date mainly from the 1980s and 1990s; ipamorelin’s human data are early pharmacokinetic studies.

Is CJC-1295 with ipamorelin different from tesamorelin?

Yes. The blend pairs a GHRH-receptor agonist with a ghrelin-receptor agonist, so two pathways are engaged. Tesamorelin engages only the GHRH receptor, but does so with a molecule that is closer to the natural hormone and better characterised clinically.

How does MK-677 fit in?

MK-677 (ibutamoren) is an orally active small molecule, not a peptide, that acts on the same ghrelin receptor as ipamorelin. In older adults it raised GH and IGF-I by enhancing existing pulsatile secretion.

Can these be ranked from weakest to strongest?

No, because they are measured in different studies with different endpoints and no head-to-head trial exists. Comparing them meaningfully requires matching the receptor, the readout and the time course.